The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform

Wensheng Fan - One of the best experts on this subject based on the ideXlab platform.

  • a randomized open label clinical trial of an anti hpv Biological Dressing jb01 bd administered intravaginally to treat high risk hpv infection
    Microbes and Infection, 2016
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan, Shufang Jiang, Qianqing Wang
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical Biological agent for the treatment of cervical HPV infection.

  • A randomized open-label clinical trial of an anti-HPV Biological Dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection.
    Microbes and infection, 2015
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P 

Xuetao Guo - One of the best experts on this subject based on the ideXlab platform.

  • a randomized open label clinical trial of an anti hpv Biological Dressing jb01 bd administered intravaginally to treat high risk hpv infection
    Microbes and Infection, 2016
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan, Shufang Jiang, Qianqing Wang
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical Biological agent for the treatment of cervical HPV infection.

  • A randomized open-label clinical trial of an anti-HPV Biological Dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection.
    Microbes and infection, 2015
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P 

E A Vorotelyak - One of the best experts on this subject based on the ideXlab platform.

  • tissue engineered Biological Dressing accelerates skin wound healing in mice via formation of provisional connective tissue
    Histology and Histopathology, 2018
    Co-Authors: E S Chermnykh, Ekaterina V Kiseleva, Olga S Rogovaya, Aleksandra L Rippa, A V Vasiliev, E A Vorotelyak
    Abstract:

    Despite recent advances in bioengineered therapies, wound healing remains a serious clinical problem. In acute full-thickness wounds, it is desirable to replace both the damaged dermis and epidermis in a single procedure. This approach requires appropriate properties of tissue-engineered Dressings to support simultaneous regenerative processes in the dermis and epidermis while they are temporally separated in the natural wound healing process. In this study, a collagen-based scaffold inhabited by skin cells was employed. Its ability to stimulate the skin repair of full-thickness excisional splinting wounds in a murine model was evaluated in comparison with that of acellular collagen and commercially available gelatin porous sponge Spongostan®. The study showed that cell-based skin equivalent promoted the immediate filling of the wound bed and provided simultaneous reorganization of the dermal component into highly vascularized granulation-like tissue and rapid epithelialization, thus improving the quality of healing. Inflammation was delayed and less pronounced. In contrast, acellular collagen and especially Spongostan® failed to demonstrate similar results. The porous structure of Spongostan® prevented effective long-term epithelialization and impeded the formation of an adequate connective tissue at the wound bed.

Qianqing Wang - One of the best experts on this subject based on the ideXlab platform.

  • a randomized open label clinical trial of an anti hpv Biological Dressing jb01 bd administered intravaginally to treat high risk hpv infection
    Microbes and Infection, 2016
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan, Shufang Jiang, Qianqing Wang
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical Biological agent for the treatment of cervical HPV infection.

Ke Huang - One of the best experts on this subject based on the ideXlab platform.

  • a randomized open label clinical trial of an anti hpv Biological Dressing jb01 bd administered intravaginally to treat high risk hpv infection
    Microbes and Infection, 2016
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan, Shufang Jiang, Qianqing Wang
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical Biological agent for the treatment of cervical HPV infection.

  • A randomized open-label clinical trial of an anti-HPV Biological Dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection.
    Microbes and infection, 2015
    Co-Authors: Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Ke Huang, Wensheng Fan
    Abstract:

    Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV Biological Dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P